Objectives: To investigate the impact of depression and its treatment on health-related quality of life (HRQoL) in a naturalistic, primary care setting in the UK.
INTRODUCTION
The concept of health was defined by the World Health Organization in 1948 as ''a state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity'' [1] . This was later refined into five dimensions of health-related quality of life (HRQoL) encompassing physical, social, psychological, overall life satisfaction/ wellbeing and perceptions of health status at the 1993 International Consensus Conference [2] . HRQoL is used to assess both functional outcome and quality of life (QoL) across disease states and has been demonstrated to be impaired in depressed patients compared to both the general population and to people with chronic medical conditions such as diabetes, arthritis, and heart disease [3] [4] [5] . It is therefore
important to understand what factors influence HRQoL in depression and how these influence response to treatment. The five dimensions of HRQoL can be assessed using tools such as the Short Form 36 Health Status Survey (SF-36) [6] and European Quality of Life-5 Dimensions (EQ-5D) [7] and although studies have previously assessed the effectiveness of antidepressant treatments on HRQoL [8] [9] [10] [11] [12] [13] further research is needed in order to improve our understanding of factors related to HRQoL and its improvement during treatment. Two possible moderators of HRQoL in depression are somatic and pain symptoms. Many depressed patients present with somatic symptoms [14] and there is a strong association between depression and painful symptoms in primary care [15] . It is known that painful symptoms adversely affect treatment outcomes in depression [16] , but less is known about their impact on HRQoL outcomes.
The European Factors Influencing Depression Endpoints Research (FINDER)
observational study [17] [18] [19] was designed to increase understanding of the factors that influence HRQoL outcomes for clinically depressed outpatients receiving antidepressant medication in routine primary and secondary care. In this study, pain and its impact on functioning were also assessed using patientreported measures. A strength of this study is that it included patients with other chronic medical comorbidities that may influence HRQoL and outcomes, and so is more reflective of the clinical populations found in primary care than those from randomized controlled trials in which greater use of exclusion criteria is normal. The findings from naturalistic observational studies such as FINDER may therefore be generalizable to a larger population and can be used to provide direction for further research [20] .
The primary objective of this paper is to estimate the HRQoL of a primary care depressed population at baseline (untreated) and 3 and 6 months after initiation of antidepressant treatment. A shared secondary objective was to determine the factors associated with HRQoL at baseline and 6 months. Additional, post hoc secondary objectives specific to the UK sample were: to describe the impact of caseness for depression at baseline on HRQoL; to describe the impact of pain (explained medical cause/ unexplained medical cause) at baseline on HRQoL; to describe changes in overall pain and pain interference outcomes by pain cohort (explained medical cause/unexplained medical cause); and to summarize antidepressant use by pain cohort (explained medical cause/ unexplained medical cause).
The authors are not aware of any other paper which has sought to bring together outcomes as measured by QoL with the factors that influence outcomes as described above, making this an innovative paper with a particular relevance to primary care.
METHODS

Study Design
The UK subset of the FINDER study was designed as a prospective, noninterventional, observational study to measure QoL in patients diagnosed as having depressive disorder by their general practitioner (GP) and initiated on antidepressants. The results of the full European study have already been published elsewhere [17] [18] [19] . Here, the authors report the study design and findings from the UK cohort of patients only. 
HRQoL and the Effect of Pain
Three pain subgroups are described: those with no or mild pain; those with moderate/severe pain with a defined medical disorder known to cause pain as based on physician selection of listed comorbidities (termed explained pain); and those with moderate/severe pain with a defined medical disorder not associated with pain or without further comorbidity other than depression (termed unexplained pain). Pain was assessed in the study using the overall pain VAS, in which a score of 0-30 represented no/mild pain and a score over 30 represented moderate/ severe pain. For HRQoL and VAS pain scores in the overall sample and in the three pain cohorts, if the 95% two-sided confidence intervals (CI) for the means at two time points or for two cohorts did not overlap, the difference was considered statistically significant as this procedure corresponds to a conservative two-sided test at the 5% level.
RESULTS
A total of 608 patients was enrolled in the study in the UK by 58 participating doctors, of whom 57 were GPs.
Patient Characteristics at Baseline
The baseline characteristics of eligible patients are summarized in Table 1 other drugs only, and 5% combinations of antidepressants.
Health-Related Quality of Life significantly below general population norms.
There were improvements in HRQoL (except SF-36 PCS) at 3 months with further small improvements at 6 months.
The independent variables significantly associated with HRQoL at baseline are summarized in Table 2 and include SSI-somatic score, HADS-D, HADS-A, presence of moderate to severe pain, gender, occupational status, and age.
The independent variables significantly associated with changes in HRQoL from baseline to 6 months are shown in Table 3 . Numerous factors were associated with a worse HRQoL outcome: a higher SSI-somatic score at baseline, socioeconomic factors (older age, being unemployed, being married), depression variables (higher HADS-D score at baseline, more previous episodes of depression, longer duration of current depressive episode), previous psychiatric illness, comorbid functional syndromes, and treatment switching within antidepressant class during the 6-month treatment period. Factors associated with a better HRQoL outcome include female gender, older age at first episode, and higher HRQoL scores at baseline. (95% CI 27.3-32.5) at 3 months and to 27.1 (95% CI 24.4-29.9) at 6 months; the decrease from baseline to 6 months was considered significant as the 95% CIs did not overlap. The decrease from baseline was not significant at 3 months. Table 4 shows the VAS scores for overall pain and interference of pain with ability to perform daily activities by pain cohort at baseline, 3 and 6 months.
HRQoL by Caseness for Depression
The mean overall pain VAS (i.e., pain severity) was significantly reduced from baseline at 3 and 6 months in both the explained and unexplained pain cohorts. Mean VAS scores for interference of pain with ability to do daily activities were reduced from baseline at 3 and 6 months for both the explained and unexplained pain cohorts, indicating that pain interfered less with patients' ability to do daily activities. This change was significant for the unexplained pain group only. Figure 4 presents the antidepressant use patterns for the first and second 3 months of treatment in the three pain cohorts (no/mild Other -4.12
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DISCUSSION
The results of this study found that HRQoL (as measured by the SF-36 and EQ-5D) in patients with a first or new episode of depression presenting in UK primary care was below that previously reported in healthy populations. HRQoL improved during the first 3 months following antidepressant initiation, with more finding that a higher SSI-somatic score was associated with a poorer HRQoL supports previous findings of an inverse relationship between somatic symptoms and QoL [28] .
Moreover, a recent cross-sectional study in a large population of primary care patients with depression showed that numerous characteristics of somatic symptoms (number, [25] . Mean EQ-5D HSI scores were converted from a 0-1 scale to a 0-100 scale. The solid line represents the UK general population norms (EQ-5D VAS mean 82.5; EQ-5D HSI mean 86) [26] . EQ-5D European Quality of Life-5 Dimensions, EX/P explained pain, HSI health status index, HRQoL health-related quality of life, MCS mental component summary, N/MP no/mild pain, PCS physical component summary, SD standard deviation, SF-36 Short Form 36 Health Status Survey, UNEX/P unexplained pain, VAS visual analog scale disability, persistence) were associated with a decreased QoL [29] . Higher SSI-somatic scores were also associated with worse HRQoL outcomes over time, highlighting the continuing impact of (nonpainful) somatic symptoms on HRQoL. Somatic symptoms have been found to be associated with pain and improvement in pain outcomes in the European cohort of the FINDER study [30] . As the presence of painful symptoms has been shown to compromise outcomes of antidepressant treatment [16, 31] , so the results of this study suggest that nonpainful physical symptoms as well as painful symptoms should be taken into account when maximizing treatment response in depression. An important finding was that those patients who switched antidepressant treatment within the same antidepressant class (e.g., SSRI) had a poorer HRQoL (SF-36 MCS, EQ-5D health state value) outcome over the 6-month follow-up period than those who had no change in treatment or who switched to a different antidepressant class. Switching between antidepressant classes (e.g., SSRI to SNRI) was not significantly associated with poorer HRQoL outcome. These findings suggest that if a change in treatment is necessary, it may be more advantageous in terms of HRQoL to switch from one antidepressant class to another. This should be explored in more detail in a controlled setting.
The association of sociodemographic and depression-related factors with changes in HRQoL remain consistent with the European analysis [19] . Pain cohort (no pain or either explained or unexplained pain) was not significantly associated with change in HRQoL in the UK sample, despite significant results in the univariate analysis and an association with baseline HRQoL. Pain was associated with worse HRQoL (SF-36 MCS only) in the European analysis (P = 0.026) using the overall pain VAS score rather than pain cohorts [19] . It is likely No/mild pain was defined as an overall pain VAS B30 at baseline; both the explained and unexplained pain groups had an overall pain VAS [30 at baseline CI confidence interval, VAS visual analog scale a Overall pain severity was rated by patients on a 100 mm VAS in which 0 = no pain and 100 = pain as severe as I can imagine b Interference of overall pain with ability to perform daily activities was rated by patients on a 100 mm VAS with 0 = not at all to 100 = complete that lack of sensitivity of the pain cohort compared to that of the pain VAS score, in addition to the smaller sample size in the UK, account for this discrepancy.
Only a few previous studies have used EQ-5D to assess HRQoL in depressed patients in primary care [13, 32, 33] . In a naturalistic, longitudinal, primary care study in Sweden [33] , the EQ-5D VAS scores at baseline (40) and after 6 months of antidepressant treatment (63) were similar to those found in the present study (47 and 68, respectively, at baseline and 6 months). The same was true for the EQ-5D health state values. Nevertheless, despite improvement during 6 months of follow-up, the mean EQ-5D scores in the present study remained below the European population norms by almost 1 SD [26] .
Using the patient-rated HADS-D score of 8 or greater as a cut-off due to high sensitivity and specificity in general practice [22] , the majority of patients (82%) recruited into the UK FINDER study met the criteria for caseness for depression. This supports the view that UK The reduction in pain severity (measured using the overall pain VAS) for the whole Fig. 4 Antidepressant use in the first 3 months (0-3 months) and second 3 months (3-6 months) of treatment by pain cohort. Clinically significant pain was defined as overall pain VAS greater than 30 mm at baseline.
SNRI serotonin noradrenaline reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, VAS visual analog scale patient cohort was only statistically significant at the 6-month post baseline assessment. However, when patients with no/mild pain were separated from those with moderate/severe pain, there were significant reductions in the overall pain VAS score at both 3 and 6 months in patients with medically explained and those with unexplained pain, which exceeded the 12 mm threshold for a minimum clinically significant difference reported by Kelly [34] . Despite the above finding, the cohort with unexplained pain at baseline still had moderate pain at the end of the study (mean overall pain VAS 36.4). Furthermore, pain interference with daily activities was still significantly impaired in the unexplained pain cohort compared with the no/ mild pain cohort (mean VAS 33.9 vs. 10.2). This observation suggests that by 6 months, the antidepressant treatments that were given in the study (which were mainly SSRIs) were neither very effective at treating the painful somatic symptoms in depression nor at minimising the associated disability.
Antidepressant use patterns in this UK general practice study were in accordance with the National Institute for Health and Clinical Excellence guidelines for depression [35] , which were published halfway through recruitment The study has several limitations in addition to those common to observational studies due to the lack of randomization, such as selection and observer bias. First, the observation period was limited to 6 months, so it is unclear if HRQoL would become comparable to population norms with further treatment, or if a deficit would remain for those with pain on current treatment. Conversely, due to the episodic nature of depression, it is possible that improvement in depression and related HRQoL in some subjects over the 6-month period represents the natural course of the illness rather than improvement related to any treatment given. Furthermore, without a control group, improvement could represent regression towards the mean. Second, during the second 3-month period of the study, 15-22% of patients in each group were not receiving drug treatment, and it is unclear how this may have affected HRQoL outcome overall and in the different pain cohorts. Finally, the results do not reflect the complete spectrum of patients presenting with depression in primary care, but those in whom mutual agreement between clinician and patient has resulted in a course of antidepressants. The ThREshold for AntiDepressant response (THREAD) study [38] conducted in UK general practice found that many patients, albeit with mild to moderate depression, declined to receive antidepressants.
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